The expanded offerings include a collection of validated models and services for in vivo pharmacodynamic and efficacy studies, including multi-color flow cytometry, immunohistochemistry, and multiplex ELISA.
According to Jean Pierre Wery, President of Crown Bioscience, the additions come in response to a growing demand for immuno-oncology services - a market which is expected to see annual revenues of $25bn to $40bn by 2020, according to a report by Tufts.
“In particular, single cell-based FACS analysis has become a standard and essential tool to investigate the impact of Immuno-Oncology therapy in both murine and humanized systems in the preclinical setting,” said Henry Li, VP of Translational Oncology at Crown Bioscience.
“The ability to gate different sub-populations of T lymphocytes and myeloid compartment provides a rapid way for our clients to understand the impact of both single and combination therapies to significantly extend the reach of potential therapeutic effect across a larger population of patients.”.
The company’s collection of syngeneic models, as well as its MiXeno™, MuPrime™, HuGEMM™ and humanized PDX platforms, can all be profiled using the immunophenotyping capacities for both pretreatment baseline and post treatment pharmacodynamic readouts.
The announcement follows CrownBio’s launch of its high throughput-screening platform, HuScreen in May. As Outsourcing-Pharma.com previously reported, the platform seeks to improve preclinical studies using patient-derived xenograft (PDX) models.